The pro-oncogenic NR4A1-regulated activities have previously been characterized in colon, lung and pancreatic cancer cells [12, 16, 18, 19], and the C-DIM/NR4A1 antagonists inhibited these pathways (Figure 1B) and gave results comparable to those observed for RNA interference (RNAi). Here, NR4A1 is linked to pancreatic neoplasm.